ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010

posted in: News | 0

ARMO BioSciences, Inc., a late-stage immuno-oncology  company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with FOLFOX chemotherapy for the treatment of patients with advanced pancreatic cancer. These data are being presented in a poster session today at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago, Illinois. AM0010 is being evaluated in an ongoing Phase 1b clinical trial that has enrolled 352 advanced cancer patients.

“We are very encouraged that our novel immunotherapy AM0010 in combination with FOLFOX induced prolonged objective responses, including partial and complete responses, and led to a median overall survival of 10.0 months in patients with advanced pancreatic cancer that previously had been treated with a median of two prior therapies,” said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences.  “We are excited to conduct our ongoing pivotal Phase 3 clinical trial of AM0010 in combination with FOLFOX as second-line therapy for advanced metastatic pancreatic cancer. We are committed to our goal of developing new immune-based treatment options for patients living with difficult-to-treat solid tumors.”

Press Release